Saad F - Search Results

1

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, Oscroft E, Barker L, Degboe A, Clarke NW. Saad F, et al. Eur Urol Oncol. 2024 Apr 5:S2588-9311(24)00082-8. doi: 10.1016/j.euo.2024.03.006. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38582650 Free article.

2

Role of bisphosphonates in prostate cancer.

Saad F, Schulman CC. Saad F, et al. Eur Urol. 2004 Jan;45(1):26-34. doi: 10.1016/j.eururo.2003.10.003. Eur Urol. 2004. PMID: 14667511 Review.

3

Natural history and treatment of bone complications in prostate cancer.

Saad F, Clarke N, Colombel M. Saad F, et al. Eur Urol. 2006 Mar;49(3):429-40. doi: 10.1016/j.eururo.2005.12.045. Epub 2006 Jan 6. Eur Urol. 2006. PMID: 16431012 Review.

4

Poor overall survival in septa- and octogenarian patients after radical prostatectomy and radiotherapy for prostate cancer: a population-based study of 6183 men.

Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N, Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Jeldres C, et al. Among authors: saad f. Eur Urol. 2008 Jul;54(1):107-16. doi: 10.1016/j.eururo.2007.10.038. Epub 2007 Oct 30. Eur Urol. 2008. PMID: 17996358

5

High provider volume is associated with lower rate of secondary therapies after definitive radiotherapy for localized prostate cancer.

Jeldres C, Suardi N, Saad F, Montorsi F, Shariat SF, Perrotte P, Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. Jeldres C, et al. Among authors: saad f. Eur Urol. 2008 Jul;54(1):97-105. doi: 10.1016/j.eururo.2007.10.070. Epub 2007 Nov 6. Eur Urol. 2008. PMID: 17997022

6

Castration-resistant prostate cancer: from new pathophysiology to new treatment targets.

Chi KN, Bjartell A, Dearnaley D, Saad F, Schröder FH, Sternberg C, Tombal B, Visakorpi T. Chi KN, et al. Among authors: saad f. Eur Urol. 2009 Oct;56(4):594-605. doi: 10.1016/j.eururo.2009.06.027. Epub 2009 Jun 24. Eur Urol. 2009. PMID: 19560857 Review.

7

Zoledronic Acid improves clinical outcomes when administered before onset of bone pain in patients with prostate cancer.

Saad F, Eastham J. Saad F, et al. Urology. 2010 Nov;76(5):1175-81. doi: 10.1016/j.urology.2010.05.026. Urology. 2010. PMID: 21056263 Clinical Trial.

8

Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.

Saad F, Segal S, Eastham J. Saad F, et al. Eur Urol. 2014 Jan;65(1):146-53. doi: 10.1016/j.eururo.2012.05.007. Epub 2012 May 12. Eur Urol. 2014. PMID: 22633317 Clinical Trial.

9

New and emerging therapies for bone metastases in genitourinary cancers.

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K. Saylor PJ, et al. Among authors: saad f. Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23. Eur Urol. 2013. PMID: 23201471 Free PMC article. Review.

10

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD. Gartrell BA, et al. Among authors: saad f. Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Eur Urol. 2014. PMID: 23706567 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,348 results

Search Page